A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK-1903 in Patients with Dyslipidemia
Latest Information Update: 10 May 2022
At a glance
- Drugs MK 1903 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 11 Apr 2019 This trial has been completed in Finland, according to European Clinical Trials Database.
- 08 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 08 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.